Drugs / Bio-008
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06027346 | Jul 2023 → May 2026 | cancer | Shijiazhuang Yiling Pharmaceutical Co. Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bio-008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06027346 ↗ |
| Route | Intravenous | “administered intravenously (ivd)” NCT06027346 ↗ |